Plantago ovata seed

This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Plantago ovata seedis a plant extract indicated in the treatment of occasional constipation.

Generic Name
Plantago ovata seed
DrugBank Accession Number
DB14585
Background

Not Available

Type
Biotech
Groups
Approved, Experimental, Investigational
Synonyms
  • Blond psyllium
  • Blonde psyllium
  • Indian plantain seed
  • Indian psyllium
  • Ispaghul
  • Ispaghula
  • Ispaghula额外ct
  • Ispaghula husk
  • Ispaghula seed
  • Plantaginis ovatae semen
  • Plantaginis ovatae testa
  • Plantago brunnea seed
  • Plantago fastigiata seed
  • Plantago gooddingii seed
  • Plantago insularis seed
  • Plantago minima seed
  • Psyllium seed, blonde

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

半衰期

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Plantago ovata seed.
Aclidinium The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Aclidinium.
Alfentanil The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Alfentanil.
Alloin The risk or severity of adverse effects can be increased when Plantago ovata seed is combined with Alloin.
Amantadine The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amantadine.
Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Plantago ovata seed.
Amiodarone The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amiodarone.
Amitriptyline The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amitriptyline.
Amlodipine The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amlodipine.
Amobarbital The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Amobarbital.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
CONSIGEL POWDER FOR ORAL SOLUTION 3.5G Powder 3.5克 Oral XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD 2021-12-02 Not applicable Malaysia flag
EVAGEL POWDER FOR ORAL SOLUTION 3.5g Powder, for solution Oral APEX PHARMACY MARKETING SDN. BHD. 2020-09-08 Not applicable Malaysia flag
FYBOGEL ORANGE Granule 3.5 g Oral บริษัท เรกคิทท์ เบนคีเซอร์ (ประเทศไทย) จำกัด 1994-12-22 Not applicable Thailand flag
FYBOGEL ORANGE SACHET Powder, for solution Oral RB (HEALTH) MALAYSIA SDN BHD 2020-09-08 Not applicable Malaysia flag
Mucilin Powder 2.45 g/5g Oral Paradigm Pharmaceuticals Inc 2018-07-30 2019-12-22 US flag
MUCILIN ORANGE FLAVOUR Powder 2.45 g Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2020-08-13 Not applicable Thailand flag
MUCILIN SF Powder 3.5 g Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2020-08-13 Not applicable Thailand flag
Mucilin Sf Powder 3.5 g/5g Oral Paradigm Pharmaceuticals Inc 2018-07-30 2019-12-22 US flag
MUCILIN SF Powder 3.5 g Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2017-10-11 Not applicable Thailand flag
MUCILIN SF MIXED BERRY FLAVOUR Powder 3500 mg Oral บริษัท เบอร์ลินฟาร์มาซูติคอลอินดัสตรี้ จำกัด 2016-02-04 Not applicable Thailand flag
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
อาจิโอแล็กซ์ Plantago ovata seed(52 G/100G)+Plantago seed(2.2 G/100G)+Senna leaf(0.3 G/100G) Granule บริษัท เมด้า ฟาม่าร์ (ประเทศไทย) 2016-09-26 Not applicable Thailand flag

Categories

ATC Codes
A06AC51 — Ispaghula, combinations
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
K9NXW456E2
CAS number
Not Available

References

General References
  1. DailyMed: Mucilin (plantago ovata) oral powder [Link]
RxNav
104129

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
2 Terminated Treatment Syndrome, Metabolic 1
Not Available Unknown Status Treatment Fecal Incontinence 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Powder, for solution Oral
Granule Oral 79.618 g
Powder Oral 2.45 g/5g
Powder Oral 2.45 g
Powder Oral 3.5 g/5g
Powder Oral 3500 mg
Granule Oral 150 g
Granule Oral 300 g
Granule Oral 5 g
Granule Oral 175 g
Powder Oral 3.4 g
Powder Oral 49 g
Granule Oral 3.5 g
Granule
Powder Oral 3.5 g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at August 19, 2018 20:47 / Updated at May 14, 2021 01:06